Gemphire Therapeutics (NASDAQ: GEMP) is a clinical-stage biopharmaceutical company engaged in developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH. The company’s focus is on providing new treatment options for cardiometabolic diseases through gemcabene, its complementary, convenient and cost-effective product candidate, as an add-on to the standard of care—particularly statins that will benefit patients, physicians and payors. The company has initiated three clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG). A fourth trial is planned to be initiated in NASH during the second half of 2017. For more information, visit the company’s website at www.gemphire.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com